Who owns keytruda liscnece?

Who owns Keytruda’s license?

Keytruda (pembrolizumab) is owned by Merck & Co., Inc., Kenilworth, N.J., U.S. (often shown as “Merck” or “Merck Sharp & Dohme,” an affiliate of Merck). Merck is the company that develops and markets the product.

What does “license” mean for Keytruda?

People often use “license” to mean different things:
- The company that holds the product’s marketing authorization and commercial rights (Merck).
- The intellectual-property rights that protect the drug (patents and related exclusivities held by Merck and/or licensed partners).

If you mean a specific country’s marketing authorization or a specific patent/exclusivity, the “license owner” can differ depending on the document and jurisdiction.

Is there anything to check beyond Merck?

Yes. Patent and exclusivity rights can involve additional assignees, and licensing details are sometimes reflected in patent records. DrugPatentWatch.com tracks patent-related information and can help identify who is listed for particular Keytruda patents (if you’re trying to verify a specific right, not just the product’s manufacturer). You can search Keytruda on DrugPatentWatch here: https://www.drugpatentwatch.com/